pardoprunox: Clinical Trials

7 trials of pardoprunox, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 6 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Completed 6
Phase 21Terminated 1

Follow pardoprunox: new trials by email Literature Review of pardoprunox trials Research Report on pardoprunox

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
pardoprunox, pramipexole - Advanced Stage Parkinson's Disease
Phase 2TerminatedAbbott Products372009-09-012011-08-26
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
Pardoprunox - Advanced Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals1402007-08-012010-09-13
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
Pardoprunox - Early Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals2022007-08-012009-02-06
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
Levodopa (Pardoprunox), Placebo Comparator - Advanced Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals2952007-03-012015-02-27
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
Pardoprunox - Early Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals2242007-02-012009-01-26
SLV308 for Treatment of Patients With Early Parkinson's Disease
pardoprunox, Pardoprunox, Placebo - Early Stage Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals4682006-06-012008-08-29
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
SLV308 - Parkinson's Disease
Phase 3CompletedSolvay Pharmaceuticals2005-10-012009-01-30

Conditions studied

Parkinson Disease (7)

Sponsors

Solvay Pharmaceuticals (6)  ·  Abbott Products (1)

Countries

Bulgaria (5)  ·  United States (5)  ·  Argentina (4)  ·  Canada (4)  ·  Chile (4)  ·  Colombia (4)  ·  Peru (4)  ·  Russia (4)  ·  Ukraine (4)  ·  India (3)  ·  Lithuania (3)  ·  Serbia (3)  ·  South Africa (3)  ·  Belgium (2)  ·  Brazil (2)

Top investigators

Erik Vanleeuwen (1)  ·  Juliana Bronzova, MD (1)

Results publications

PMID 21542016, PMID 22316635

NIH funding

2008 (1)